Recently, high levels of EP300 were correlated to both prostate cancer progression and chemotherapy resistance in metastatic CRPC patients, and it has emerged as a possible co-target in chemo-resistant prostate cancer treatment [79]. Here, EP300 is linked to prostate carcinoma.